Is Akoya Biosciences, Inc. overvalued or undervalued?

As of 8 November 2021, Akoya Biosciences, Inc. has moved from a grade of "does not qualify" to "risky." The company is currently considered overvalued. Key ratios reveal significant concerns, including a Price to Book Value of -9.82, an EV to EBIT of -2.94, and an EV to EBITDA of -3.70, all indicating financial distress and negative performance metrics.
In comparison to its peers, Akoya's valuation is notably worse than Xeris Biopharma Holdings, Inc., which has a P/E of -15.77 and an EV to EBITDA of -91.03, and Nuvation Bio, Inc., with an EV to EBITDA of -0.62. The negative return on capital employed (ROCE) of -80.86% further underscores the company's challenges. Additionally, Akoya's stock has underperformed significantly against the S&P 500, with a year-to-date return of -43.67% compared to the index's 2.44%.